The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections
The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections
复制标题
DOI：
10.1016/j.ijantimicag.2007.07.037
复制
发表时间：
2007-12-01
影响因子：
10.8
通讯作者：
Ball, Peter
中科院分区：
文献类型：
--
作者：
Ball, Peter
到了 20 世纪 60 年代和 70 年代，抗菌治疗感染的问题开始出现。以前的活性抗菌药物因耐药性的产生而受到损害。在葡萄球菌、大肠杆菌、奇异变形杆菌、流感嗜血杆菌和卡他莫拉菌等分离株中发现了β-内酰胺酶的产生。因此，有效的β-内酰胺酶抑制剂克拉维酸的发现及其对阿莫西林的保护作用，阿莫西林是一种半合成青霉素，具有良好的口服吸收性和有效的广谱抗菌活性，因此对于细菌性疾病的治疗具有重要意义。在对支气管炎和尿路感染进行初步临床研究后，阿莫西林/克拉维酸疗法在多种感染中进行了研究，并被证明具有高水平的临床疗效。这些结果支持了1981年阿莫西林/克拉维酸（Augmentin）的上市，用于治疗上下呼吸道感染、尿路感染、皮肤和软组织感染以及产科、妇科和腹腔内感染。 (C) 2007 Elsevier B.V. 和国际化疗协会。版权所有。
By the 1960s and 1970s, problems in the antibacterial treatment of infections had begun to emerge. Previously active antibacterials were being compromised by the development of resistance. Beta-lactamase production was identified in isolates of staphylococci, and, amongst others, in Escherichia coli, Proteus mirabilis, Haemophilus influenzae and Moraxella catarrhalis. The discovery of the potent beta-lactamase inhibitor clavulanic acid, and its protective effect on amoxicillin, a semi-synthetic penicillin with good oral absorption and potent broad-spectrum antimicrobial activity, was thus of great importance in the treatment of bacterial disease. Following preliminary clinical studies in bronchitis and urinary tract infections, amoxicillin/clavulanate therapy was investigated in a wide range of infections and proved to demonstrate a high level of clinical efficacy. These results supported the launch of amoxicillin/clavulanate (Augmentin) in 1981 for use in upper and lower respiratory tract infections, urinary tract infections, skin and soft tissue infections and obstetric, gynaecological and intra-abdominal infections. (C) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.